Giusi Cavezza

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar et al. · Clinical Infectious Diseases · 2018 · 126 citations

Life Sciences, Infectious Diseases, Microbiology +17

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin et al. · Clinical Microbiology and Infection · 2020 · 78 citations

Life Sciences, Infectious Diseases, Pharmacology +16

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol

Yaakov Dickstein, Leonard Leibovici, Dafna Yahav et al. · BMJ Open · 2016 · 45 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study

Yael Zak-Doron, Yael Dishon Benattar, Iris Pfeffer et al. · Clinical Infectious Diseases · 2018 · 45 citations

Pharmacy, Infectious Diseases, Microbiology +17

Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections

Emanuele Durante‐Mangoni, R. Andini, Simona Signoriello et al. · Clinical Microbiology and Infection · 2016 · 37 citations

Life Sciences, Infectious Diseases, Nephrology +17